Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00932971 | HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis | PHASE2 | COMPLETED | 70 | — | — | Jun 1, 2009 | Aug 2, 2017 | Jan 29, 2018 | 10 | Germany, Greece +1 |
| Arm | Type | Description |
|---|---|---|
| PEG-IFN alfa-2a plus placebo | PLACEBO_COMPARATOR | Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally |
| PEG-IFN alfa-2a plus Tenofovir | ACTIVE_COMPARATOR | Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally |
| Name | Type | Description |
|---|---|---|
| PEG-IFN alfa-2a, Tenofovir | DRUG | Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally |
| PEG-IFN alfa-2a, placebo | DRUG | Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally |
Inclusion Criteria: * Written informed consent. * Age \> 18 years. * Positive HBsAg, for at least the prior 6 months, positive anti-HDV for at least 3 months and positive for HDV-RNA by PCR within the screening period. * Elevated serum ALT ≥ ULN but ≤ 10X ULN as determined by two abnormal values ta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | MIRM | 4 | PHASE3 | Brelovitug, Bulevirtide and Brelovitug -, Delayed Treatment with Brelovitug, Bulevirtide |
| Vir Biotechnology, Inc. | VIR | 1 | PHASE2 | VIR-2218, VIR-3434, NRTI |
| Gilead Sciences, Inc. | GILD | 2 | PHASE1 | GS-4321, Bulevirtide |